Selinexor Significantly Prolongs PFS in Advanced/Recurrent Endometrial Cancer, Warranting sBLA SubmissionFebruary 8th 2022
Statistically significant improvement in progression-free survival has been shown with selinexor in patients with advanced or recurrent endometrial cancer, including those with wild-type p53.
Biomarkers Improve Targeting and Risk Assessment in Endometrial CancerFebruary 5th 2022
In an interview with Targeted Oncology, Casey M. Cosgrove, MD, discussed the current state of biomarkers for patients with endometrial cancer and how they can be used for prognostic purposes.
Survival Benefit of Lenvatinib/Pembrolizumab in Advanced Endometrial Cancer Confirmed, Securing FDA IndicationJanuary 25th 2022
Globally, there is no established standard of care treatment for this patient population once patients failed on front-line platinum-based chemotherapy. Lenvatinib plus pembrolizumab is a new option.
Phase 3 Trial to Determine the Potential Superiority of Pembrolizumab/Lenvatinib vs Chemotherapy in Advanced Endometrial CancerJanuary 21st 2022
Pending results from the ENGOT-en9/LEAP-001 will determine whether the combination of pembrolizumab and lenvatinib prolongs survival more than chemotherapy in patients with endometrial cancer.
ICIs Provide New Treatment Options for Subtypes of Endometrial CancerDecember 30th 2021
In a presentation during the 39th Annual Chemotherapy Foundation Symposium, Bhavana Pothuri, MD, MS, explained the recent advances in subtypes and treatment options for patients with endometrial cancer.
Sarcopenic Obesity Associated with Worse OS Outcomes in Endometrial CancerOctober 28th 2021
While some studies have found that obesity provides a survival advantage in certain cancers, sarcopenia obesity was found to be associated with worse survival outcomes in patients with endometrial cancer.
Promising Safety/Efficacy Signals Shown With Lenvatinib Plus Weekly Paclitaxel in Endometrial CancerOctober 14th 2021
Currently, no FDA-approved therapies are available to address the need of patients with advanced/recurrent endometrial cancer, underscoring a need to develop novel strategies like the combination of lenvatinib and weekly paclitaxel.
Racial Disparities Persist Among Women With Endometrial Cancers in Equal-Access Healthcare SystemsOctober 14th 2021
Despite researchers compiling data from an equal-access system and adjusting for age, diagnosis period, tumor stage, tumor histology/grade, and whether the patient had adjuvant treatment, the overall survival disparity between Black and White women with endometrial cancer persisted.
High Responses to Dostarlimab in Endometrial Cancer Linked to TMB-H StatusSeptember 16th 2021
High responses to single-agent dostarlimab-gxly were seen in patients with endometrial cancer who had a high tumor mutational burden, irrespective of mismatch repair or microsatellite stability status.
DUO-E Trial Explores 1L Durvalumab Maintenance With or Without Olaparib in Advanced/Recurrent Endometrial CancerAugust 15th 2021
In an interview with Targeted Oncology™, Shannon N. Westin, MD, MPH, FACOG, discussed the need for the DUO-E trial in the endometrial cancer space and the unique patient population the study will evaluate.
Westin Explains the Need for Novel Therapies in the Endometrial Cancer SpaceAugust 14th 2021
Shannon Westin, MD, MPH, FACOG, a gynecologic oncologist at The University of Texas MD Anderson Cancer Center, discusses the use of durvalumab with or without olaparib for the treatment of endometrial cancers.
FDA Accepts sBLA for Pembrolizumab Monotherapy for Endometrial CancerAugust 10th 2021
The FDA has accepted a new supplemental biologics license application for pembrolizumab, an anti-PD-1 therapy, as a single agent for the treatment of patients with advanced endometrial carcinoma that is microsatellite instability-high or mismatch repair deficient, who have diseased progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.
NRG-GY012 Study in Recurrent or Metastatic Endometrial Cancer Adds Treatment ArmsJuly 29th 2021
In an interview with Targeted Oncology, Bobbie J. Rimel, MD, discussed the phase 2 NRG-GY012 results and the next step for cediranib plus olaparib as treatment of recurrent or metastatic endometrial cancer.
FDA Approves Lenvatinib/Pembrolizumab for Select Patients With Advanced Endometrial CancerJuly 22nd 2021
The FDA has approved the combination of lenvatinib and pembrolizumab for the treatment of patients with advanced endometrial cancer that is not microsatellite instability–high or mismatch repair deficient, who have disease progression following prior systemic treatment and who are not candidates for curative surgery or radiation.